Tudor Investment Corp ET AL Purchases New Stake in LifeStance Health Group, Inc. $LFST

Key Points

• Tudor Investment Corp purchased a new stake of 189,038 shares in LifeStance Health Group (NASDAQ:LFST) in Q3, valued at about $1.04 million.
• LifeStance reported revenue growth of 17.4% to $382.2 million but missed EPS expectations ($0.03 vs. $0.05), its board authorized a $100 million share repurchase (≈3.6% of shares), and analysts hold a Moderate Buy consensus with an average price target of $9.83.
• Director Darren M. Black sold 4,314,939 shares for roughly $30.25 million on March 2, cutting his ownership by 12.87%; insiders own 6.6% of the stock while institutional investors own 85.5%.

Tudor Investment Corp ET AL purchased a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 189,038 shares of the company's stock, valued at approximately $1,040,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LFST. Royal Bank of Canada boosted its position in LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company's stock worth $468,000 after purchasing an additional 27,244 shares during the period. AQR Capital Management LLC boosted its position in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company's stock worth $343,000 after purchasing an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company's stock worth $952,000 after purchasing an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in LifeStance Health Group by 1.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company's stock worth $4,100,000 after purchasing an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in LifeStance Health Group by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company's stock worth $2,847,000 after purchasing an additional 51,154 shares during the period. Institutional investors own 85.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LFST. UBS Group increased their target price on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Jefferies Financial Group upgraded shares of LifeStance Health Group to a "strong-buy" rating in a research report on Thursday, March 12th. Wall Street Zen upgraded shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Sunday, February 8th. BTIG Research increased their target price on shares of LifeStance Health Group from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Monday, February 2nd. Finally, Barclays increased their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $9.83.

LifeStance Health Group Price Performance

LFST stock opened at $6.46 on Tuesday. The firm has a 50 day moving average of $6.74 and a 200-day moving average of $6.48. The firm has a market capitalization of $2.52 billion, a P/E ratio of 323.16 and a beta of 1.13. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. LifeStance Health Group, Inc. has a 12 month low of $3.74 and a 12 month high of $8.09.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.02). The company had revenue of $382.20 million during the quarter, compared to analysts' expectations of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The company's revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.01) earnings per share. As a group, sell-side analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

LifeStance Health Group announced that its Board of Directors has authorized a share repurchase plan on Wednesday, February 25th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Darren M. Black sold 4,314,939 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total value of $30,247,722.39. Following the sale, the director directly owned 29,209,776 shares of the company's stock, valued at $204,760,529.76. This trade represents a 12.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.60% of the stock is owned by corporate insiders.

LifeStance Health Group Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.